Soligenix Inc (SNGX)
NASDAQ:SNGX
Want to see SNGX full AI Analyst Report?
Top Page
Soligenix
(NASDAQ:SNGX)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.32
▼(-77.71% Downside)
Action:DowngradedDate:04/30/26
The score is driven primarily by weak financial performance (minimal revenue, widening losses, and rising cash burn) and bearish technical momentum (well below moving averages with negative MACD and very low RSI). Corporate events further pressure the outlook due to the Phase 3 FLASH2 futility halt, while the improved balance sheet provides only partial support.
Positive Factors
Balance-sheet improvement
Lower leverage and a move to positive equity materially reduce near-term refinancing risk and improve solvency. This stronger capital structure gives management more optionality to pursue partnerships, M&A, or targeted development pathways without immediate distress-driven decisions.
Negative Factors
Phase 3 FLASH2 futility halt
A pivotal trial failure removes the company’s primary near-term path to commercialization for HyBryte, forcing costly dataset reanalysis and strategic shifts. This structurally reduces projected revenue potential, undermines partner interest, and increases the need for alternative programs or financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet improvement
Lower leverage and a move to positive equity materially reduce near-term refinancing risk and improve solvency. This stronger capital structure gives management more optionality to pursue partnerships, M&A, or targeted development pathways without immediate distress-driven decisions.
Read all positive factors
Soligenix (SNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.18M
Dividend YieldN/A
Average Volume (3M)293.55K
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue GrowthN/A
EPS Growth55.44%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.75
Shares Outstanding10,306,079
10 Day Avg. Volume179,673
30 Day Avg. Volume293,551
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-1.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.58K
Enterprise Value/Ebitda0.36
Forecast
1Y Price Target
$1.50Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Soligenix Business Overview & Revenue Model
Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Spec...
How the Company Makes Money
Soligenix generates revenue primarily through (1) government and nongovernment research and development funding and (2) collaborations and related payments tied to its development programs. A material component of its historical revenue has come f...
Soligenix Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
42
Neutral
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 250.00K | 33.35K |
| Gross Profit | 0.00 | -119.37K | -742.05K | -300.82K | -695.29K |
| EBITDA | -11.85M | -9.46M | -7.67M | -14.11M | -12.48M |
| Net Income | -11.08M | -8.27M | -6.14M | -13.80M | -12.55M |
Balance Sheet | |||||
| Total Assets | 9.24M | 8.97M | 9.80M | 14.28M | 26.87M |
| Cash, Cash Equivalents and Short-Term Investments | 7.94M | 7.82M | 8.45M | 13.36M | 26.04M |
| Total Debt | 358.14K | 1.48M | 3.49M | 10.24M | 9.96M |
| Total Liabilities | 3.94M | 4.85M | 7.27M | 16.75M | 16.15M |
| Stockholders Equity | 5.29M | 4.12M | 2.52M | -2.47M | 10.72M |
Cash Flow | |||||
| Free Cash Flow | -10.27M | -8.40M | -8.60M | -12.66M | -11.75M |
| Operating Cash Flow | -10.27M | -8.40M | -8.60M | -12.65M | -11.74M |
| Investing Cash Flow | -5.88K | 0.00 | 0.00 | -13.07K | -11.79K |
| Financing Cash Flow | 10.39M | 7.76M | 3.66M | 76.82K | 19.06M |
Soligenix Technical Analysis
Positive
1.44
Price Trends
1.16
Positive
1.29
Negative
1.65
Negative
Market Momentum
>-0.01
Negative
62.53
Neutral
86.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Positive. The current price of 1.44 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.16, and below the 200-day MA of 1.65, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 62.53 is Neutral, neither overbought nor oversold. The STOCH value of 86.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNGX.
Soligenix Risk Analysis
Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soligenix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $15.30M | -2.16 | -22.03% | ― | -95.92% | 96.05% | |
48 Neutral | $12.68M | -0.39 | -119.35% | ― | 498.95% | 58.40% | |
42 Neutral | $5.09M | -0.23 | -489.66% | ― | -37.06% | 80.33% | |
41 Neutral | $7.06M | ― | ― | ― | ― | ― | |
40 Underperform | $3.18M | -1.17 | -248.01% | ― | ― | 55.44% |
* Healthcare Sector Average
SNGX
Soligenix
0.31
-1.66
-84.37%
BLRX
Bioline RX Ltd Sponsored ADR
3.10
-0.06
-1.77%
CANF
Can-Fite BioPharma
3.54
-18.76
-84.13%
GOVX
GeoVax Labs
1.76
-22.49
-92.74%
AIMD
Ainos
1.75
-1.01
-36.55%
Soligenix Corporate Events
Business Operations and StrategyM&A TransactionsProduct-Related Announcements
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
Negative
Apr 28, 2026
On April 28, 2026, Soligenix reported interim results from its pivotal Phase 3 FLASH2 trial of HyBryte in CTCL, with an independent Data Monitoring Committee recommending the study be halted for futility after 18 weeks of treatment failed to repro...
Business Operations and StrategyProduct-Related Announcements
Soligenix Provides Shareholder Update on Rare Disease Pipeline
Positive
Feb 12, 2026
On February 12, 2026, Soligenix issued a shareholder update outlining clinical and corporate progress across its rare disease pipeline, including the actively enrolling confirmatory Phase 3 FLASH2 trial of HyBryte in early-stage cutaneous T‑...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.